# Risk: __Amplification of flawed data through meta-analyses__ (PBN__Risk_2333)

## Property: has_RiskISO_Impact

* [Innovation, Creativity and research](../RiskISO/PBN__RiskISO_Purpose_2)

## Property: has_RiskTechnology

* [improved evaluation and selection criteria for meta-analyses](../Technology/PBN__Technology_1929)

## Property: has_RiskSubject

* [researchers](../Stakeholder/PBN__Stakeholder_2)
* [clinicians](../Stakeholder/PBN__Stakeholder_274)

## Property: has_RiskType

* [technological](../RiskType/PBN__RiskType_5)

## Property: has_RiskISO_Purpose

* [Attractiveness](../RiskISO/PBN__RiskISO_Impact_9)

## Property: has_RiskOwner

* [researchers](../Stakeholder/PBN__Stakeholder_2)
* [clinicians](../Stakeholder/PBN__Stakeholder_274)

## Property: has_RiskMitigation

* [Meta-analyses should carefully evaluate the quality and reliability of included studies and exclude studies with flawed or fraudulent data.](../RiskMitigation/PBN__RiskMitigation_3034)

## Property: has_RiskName

Ineffective treatments may be widely adopted, causing harm to patients and wasting resources.

## Property: has_RiskDescription

Flawed or fraudulent data can be amplified through meta-analyses, leading to the endorsement of ineffective treatments.

## Property: has_RiskSource

* [watson_rise_2022](../Article/PBN__Article_173)

## Property: has_RiskGBN

* [No](../RiskGBN/PBN__RiskGBN_0)

## Property: has_RiskHealth

* [other](../RiskHealth/PBN__RiskHealth_2)

